New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 6, 2013
18:20 EDTVRTXVertex focused on programs in CF, hepatitis C and autoimmune diseases in 2013
Vertex’s key strategies and business priorities include: Focusing investment on key development programs for: Cystic Fibrosis, CF: Vertex’s CF strategy is to provide benefit to as many CF patients as possible. Hepatitis C: Vertex’s strategy in hepatitis C is to develop new all-oral treatment regimens of 12 weeks or less in duration with a goal of providing a high viral cure rate and improved tolerability. In 2013, Autoimmune Diseases: Vertex’s strategy in autoimmune diseases is to maximize the value of VX-509 across multiple autoimmune diseases globally. The company will evaluate collaborative opportunities that provide funding and capabilities to broaden and accelerate global development of VX-509. Autoimmune Diseases: Maximizing revenues and cash flow from the appropriate use of INCIVEK®(telaprevir) and KALYDECO in the U.S. and Canada and from the growth of KALYDECO in Europe and other countries 4. Maintaining financial strength to support future growth and shareholder returns.
News For VRTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 25, 2015
06:14 EDTVRTXPTC Therapeutics takeout price likely tops $100/share, said Credit Suisse
Credit Suisse yesterday raised its price target for PTC Therapeutics (PTCT) shares to $100 from $66 after Reuters reported the drug market is starting a sale process with Shire (SHPG) and Biomarin (BMRN) as possible suitors. The firm believes a takeout is a likely outcome before or after data the Phase III data expected to be announced in October. PTC has Translarna Phase III trials ongoing in Duchenne muscular dystrophy and cystic fibrosis to support full approval in the U.S. Credit Suisse said yesterday in a note to investors that a takeout value for the company likely exceeds $100 per share. It believes PTC would be a good fit for Vertex (VRTX), Biogen (BIIB), Roche (RHHBY) and others. The firm kept an Outperform rating on the stock. PTC Therapeutics shares closed yesterday up $6.20 to $71.16.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use